ACCP Evidence-Based Clinical Practice Guidelines
暂无分享,去创建一个
D. Mccrory | R. Barst | D. Badesch | G. Simonneau | V. McLaughlin | S. Abman | G. Ahearn
[1] S. Braman. Chronic Cough Due to Acute Bronchitis , 2006, Chest.
[2] S. Braman. Chronic Cough Due to Chronic Bronchitis , 2006, Chest.
[3] M. Rosen. Chronic cough due to tuberculosis and other infections: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[4] L. Goldstein,et al. Cough and aspiration of food and liquids due to oral-pharyngeal dysphagia: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[5] U. Prakash. Uncommon causes of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[6] P. Dicpinigaitis. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[7] F. Mccool,et al. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[8] S. Tarlo. Cough: occupational and environmental considerations: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[9] K. Brown. Chronic cough due to nonbronchiectatic suppurative airway disease (bronchiolitis): ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[10] R. Irwin. Assessing cough severity and efficacy of therapy in clinical research: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[11] L. Boulet,et al. An empiric integrative approach to the management of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[12] M. Pratter,et al. Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[13] C. Brightling. Chronic cough due to nonasthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[14] P. Kvale. Chronic cough due to lung tumors: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[15] M. Pratter. Unexplained (idiopathic) cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[16] R. Irwin. Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[17] R. Irwin. Complications of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[18] M. Pratter. Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[19] D. Mccrory,et al. Methodology and grading of the evidence for the diagnosis and management of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[20] D. Bolser. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[21] P. Dicpinigaitis. Potential future therapies for the management of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[22] L. Boulet. Future directions in the clinical management of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[23] S. Tarlo. Peritoneal dialysis and cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[24] M. Rosen. Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[25] F. Mccool,et al. Global physiology and pathophysiology of cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[26] P. Dicpinigaitis. Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[27] K. Brown. Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[28] M. Rosen. Cough in the immunocompromised host: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[29] S. Braman. Postinfectious cough: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[30] B. Canning. Anatomy and neurophysiology of the cough reflex: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[31] Eric J Carro-Jiménez,et al. Primary pulmonary hypertension and pregnancy. , 2005, Boletin de la Asociacion Medica de Puerto Rico.
[32] Chen Wang,et al. [Surgical treatment of chronic pulmonary thromboembolism]. , 2005, Zhonghua wai ke za zhi [Chinese journal of surgery].
[33] T. Penzel,et al. Sleep apnea and pulmonary hypertension , 1986, Klinische Wochenschrift.
[34] R. Dixon,et al. Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.
[35] Ph.D. Dr. Walter J. Paulus M.D.. Endothelial control of vascular and myocardial function in heart failure , 2004, Cardiovascular Drugs and Therapy.
[36] W. Krause,et al. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man , 2004, European Journal of Clinical Pharmacology.
[37] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[38] M. Humbert,et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. , 2003, American journal of respiratory and critical care medicine.
[39] H. Okumura,et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. , 2003, Chest.
[40] W. Seeger,et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.
[41] R. Barst,et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension , 2003, Clinical pharmacology and therapeutics.
[42] G. Funk,et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. , 2003, Chest.
[43] H. Dincer,et al. Pathophysiology of pulmonary hypertension due to lung disease , 2003, Current opinion in pulmonary medicine.
[44] M. Ando,et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. , 2003, Chest.
[45] S. Rich,et al. Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension , 2003, Journal of cardiovascular pharmacology.
[46] R. Hetzer,et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. , 2003, European heart journal.
[47] V. Mathew,et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. , 2003, Indian heart journal.
[48] A. Branzi,et al. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension , 2002, European Respiratory Journal.
[49] G. Barnes,et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. , 2002, Journal of pediatric gastroenterology and nutrition.
[50] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[51] N. Pereira,et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. , 2002, The American journal of cardiology.
[52] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[53] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[54] C. Narasimhan,et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. , 2002, Indian heart journal.
[55] C. Klersy,et al. Mid term effects of pulmonary thromboendarterectomy on clinical and cardiopulmonary function status , 2002, Thorax.
[56] S. Rich,et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. , 2002, Chest.
[57] T. Shiomi,et al. Pulmonary hypertension in patients with severe obstructive sleep apnea , 2002, Psychiatry and clinical neurosciences.
[58] G. Simonneau,et al. New treatments for pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.
[59] W. Klepetko,et al. Bilateral lung transplantation with intra- and postoperatively prolonged ECMO support in patients with pulmonary hypertension. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[60] W. Seeger,et al. Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.
[61] P. Lavie,et al. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. , 2002, American journal of respiratory and critical care medicine.
[62] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[63] E. Michelakis,et al. Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension: Comparison With Inhaled Nitric Oxide , 2002, Circulation.
[64] Crispin Jenkinson,et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial , 2002, The Lancet.
[65] G. Verleden,et al. Combined liver and (heart-)lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. , 2002, Transplantation.
[66] T. Sundt,et al. Lung transplantation for pulmonary vascular disease. , 2002, The Annals of thoracic surgery.
[67] Kevin Gleeson,et al. Obstructive apnea during sleep is associated with peripheral vasoconstriction. , 2002, American journal of respiratory and critical care medicine.
[68] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[69] M. Alchanatis,et al. Daytime Pulmonary Hypertension in Patients with Obstructive Sleep Apnea , 2001, Respiration.
[70] R. Speich,et al. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. , 2001, Swiss medical weekly.
[71] B. Cairns,et al. Inhaled Nitric Oxide for Primary Pulmonary Hypertension in Pregnancy , 2001, Obstetrics and gynecology.
[72] G. Castro. [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study]. , 2001, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[73] J. Orens,et al. Lung transplantation for primary and secondary pulmonary hypertension. , 2001, The Annals of thoracic surgery.
[74] R. Ewert,et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.
[75] G. Sybrecht,et al. Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension , 2001, Circulation.
[76] M. Humbert,et al. Risk factors for pulmonary arterial hypertension. , 2001, Clinics in chest medicine.
[77] A. Arroliga,et al. Nocturnal hypoxemia is common in primary pulmonary hypertension. , 2001, Chest.
[78] William C. Cockerham. Physicians , 2001, BMJ : British Medical Journal.
[79] B. Winters,et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[80] L. Monnery,et al. Primary pulmonary hypertension in pregnancy; a role for novel vasodilators. , 2001, British journal of anaesthesia.
[81] N. Morrell,et al. Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension , 2001, Circulation.
[82] F. Narducci,et al. Use of inhaled nitric oxide for emergency Cesarean section in a woman with unexpected primary pulmonary hypertension , 2001, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[83] T. Kuriyama,et al. The influence of fractional pulse pressure on the outcome of pulmonary thromboendarterectomy. , 2001, The European respiratory journal.
[84] G. Olson,et al. Pregnancy and primary pulmonary hypertension : successful outcome with epoprostenol therapy. , 2001, Chest.
[85] M. Uematsu,et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. , 2001, American journal of respiratory and critical care medicine.
[86] K. Bremme,et al. Cesarean section under epidural ropivacaine 0.75% in a parturient with severe pulmonary hypertension , 2001, Acta anaesthesiologica Scandinavica.
[87] A. Loeckinger,et al. Sildenafil modulates hemodynamics and pulmonary gas exchange. , 2001, American journal of respiratory and critical care medicine.
[88] J. Feinstein,et al. Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension , 2001, Circulation.
[89] W. Seeger,et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. , 2001, The European respiratory journal.
[90] C W Whitney,et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. , 2001, American journal of respiratory and critical care medicine.
[91] W K Lam,et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. , 2000, American journal of respiratory and critical care medicine.
[92] J. Laaban,et al. Pulmonary arterial hypertension in patients with sleep apnoea syndrome , 2000, Thorax.
[93] H. Farber,et al. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. , 2000, American journal of respiratory and critical care medicine.
[94] I. Khan,et al. HIV-Related pulmonary hypertension: analytic review of 131 cases. , 2000, Chest.
[95] P. Kuo,et al. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. , 2000, Transplantation.
[96] W. Hurford,et al. Effects of Intravenous Zaprinast and Inhaled Nitric Oxide on Pulmonary Hemodynamics and Gas Exchange in an Ovine Model of Acute Respiratory Distress Syndrome , 2000, Anesthesiology.
[97] W. Vogel,et al. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. , 2000, Wiener klinische Wochenschrift.
[98] B. Besse,et al. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. , 2000, Circulation.
[99] K. Kerr,et al. The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. , 2000, American journal of respiratory and critical care medicine.
[100] M. Hoeper,et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. , 2000, The New England journal of medicine.
[101] C. Pedersen,et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. , 2000, The European respiratory journal.
[102] W. Seeger,et al. Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial , 2000, Annals of Internal Medicine.
[103] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[104] F. Grover,et al. Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation. , 2000, The Journal of thoracic and cardiovascular surgery.
[105] G. Snell,et al. Bilateral sequential single lung transplantation for pulmonary hypertension and Eisenmenger's syndrome. , 2000, The Annals of thoracic surgery.
[106] R. Aubry,et al. Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension. A case report. , 2000, The Journal of reproductive medicine.
[107] A. Haverich,et al. Ten years experience with lung and heart-lung transplantation in primary and secondary pulmonary hypertension. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[108] Inda,et al. A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .
[109] W. Seeger,et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. , 2000, Journal of the American College of Cardiology.
[110] Erry,et al. Prospective study of the association between sleep-disordered breathing and hypertension. , 2000, The New England journal of medicine.
[111] J. Pearl,et al. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. , 1999, The Annals of thoracic surgery.
[112] S. Rich,et al. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.
[113] M. Vayssairat. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. , 1999, The Journal of rheumatology.
[114] Y. Okano,et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.
[115] R. Wiesner,et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension , 1999, Hepatology.
[116] A. Atz,et al. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. , 1999, Anesthesiology.
[117] Crispin Jenkinson,et al. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial , 1999, The Lancet.
[118] D. Badesch,et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.
[119] A. Chaouat,et al. Improvement of pulmonary hypertension after liver transplantation. , 1999, Chest.
[120] H. Kimura,et al. Manifestation of pulmonary hypertension during REM sleep in obstructive sleep apnea syndrome. , 1999, American journal of respiratory and critical care medicine.
[121] S. Rich,et al. Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.
[122] R. Mcevoy,et al. Daytime pulmonary hemodynamics in patients with obstructive sleep apnea without lung disease. , 1999, American journal of respiratory and critical care medicine.
[123] R. Barst,et al. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.
[124] M. Landzberg,et al. Inhaled nitric oxide therapy in pregnancy complicated by pulmonary hypertension. , 1999, American journal of obstetrics and gynecology.
[125] R. Whyte,et al. Heart-lung transplantation for primary pulmonary hypertension. , 1999, The Annals of thoracic surgery.
[126] G. Maislin,et al. Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.
[127] P. Huang,et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. , 1999, The Journal of clinical investigation.
[128] G. Remuzzi,et al. Endothelin antagonists , 1999, The Lancet.
[129] K.,et al. Anaesthesia for caesarean section in the presence of severe primary pulmonary hypertension. , 1998, British journal of anaesthesia.
[130] S. Rybalkin,et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. , 1998, American journal of physiology. Lung cellular and molecular physiology.
[131] D. Ivy,et al. Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension. , 1998, The Journal of pediatrics.
[132] L. Boulet,et al. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. , 1998, Chest.
[133] M. Humbert,et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. , 1998, The European respiratory journal.
[134] D. Ivy,et al. Hemodynamic effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. , 1998, Chest.
[135] J. W. Miller,et al. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. , 1998, American journal of respiratory and critical care medicine.
[136] O. Hess,et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. , 1998, Journal of the American College of Cardiology.
[137] W R Clarke,et al. Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. , 1998, American journal of respiratory and critical care medicine.
[138] D. Ivy,et al. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. , 1998, The Journal of thoracic and cardiovascular surgery.
[139] M. Maclean. Endothelin-1: a mediator of pulmonary hypertension? , 1998, Pulmonary pharmacology & therapeutics.
[140] M. Humbert,et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.
[141] C. Howell,et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. , 1998, Transplantation.
[142] R. D. Rudic,et al. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. , 1998, The Journal of clinical investigation.
[143] B. Griffith,et al. Single- versus double-lung transplantation for pulmonary hypertension. , 1998, The Journal of thoracic and cardiovascular surgery.
[144] S. Rich,et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.
[145] E. Block,et al. A Caveolar Complex between the Cationic Amino Acid Transporter 1 and Endothelial Nitric-oxide Synthase May Explain the “Arginine Paradox”* , 1997, The Journal of Biological Chemistry.
[146] B. Sanner,et al. Pulmonary hypertension in patients with obstructive sleep apnea syndrome. , 1997, Archives of internal medicine.
[147] G. Dekan,et al. Bilateral lung transplantation for pulmonary hypertension. , 1997, Transplantation proceedings.
[148] N. Hill,et al. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. , 1997, Journal of applied physiology.
[149] T. Kuriyama,et al. The efficacy of pulmonary thromboendarterectomy on long-term gas exchange. , 1997, The European respiratory journal.
[150] B. Brundage,et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. , 1997, Journal of the American College of Cardiology.
[151] K. Maruyama,et al. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. , 1997, Circulation.
[152] R. Dixon,et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. , 1997, Journal of Medicinal Chemistry.
[153] Y. Okano,et al. Orally active prostacyclin analogue in primary pulmonary hypertension , 1997, The Lancet.
[154] A. Halbower,et al. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. , 1997, The American journal of physiology.
[155] B. Griffith,et al. Reperfusion injury in single-lung transplant recipients with pulmonary hypertension and emphysema. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[156] J P Cooke,et al. Nitric oxide synthase: role in the genesis of vascular disease. , 1997, Annual review of medicine.
[157] R. Speich,et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. , 1997, American journal of respiratory and critical care medicine.
[158] B. Clark,et al. Outcome of children with pulmonary hypertension referred for lung or heart and lung transplantation. , 1996, Transplantation.
[159] M. Petch,et al. Aging-associated endothelial dysfunction in humans is reversed by L-arginine. , 1996, Journal of the American College of Cardiology.
[160] J Benichou,et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.
[161] T. Saji,et al. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. , 1996, The American journal of cardiology.
[162] W. Auger,et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. , 1996, Chest.
[163] D. Schraufnagel,et al. Structural and pathologic changes in the lung vasculature in chronic liver disease. , 1996, Clinics in chest medicine.
[164] L. Sharples,et al. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation--early risk factors. , 1996, Transplantation.
[165] A. Chaouat,et al. Pulmonary Hemodynamics in the Obstructive Sleep Apnea Syndrome: Results in 220 Consecutive Patients , 1996 .
[166] P. Ganz,et al. Atherosclerosis: risk factors and the vascular endothelium. , 1996, American heart journal.
[167] S. Okazaki,et al. Positive inotropic and chronotropic effects of beraprost sodium, a stable analogue of prostacyclin, in isolated guinea pig myocardium. , 1996, General pharmacology.
[168] S. Nishio,et al. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. , 1996, Journal of cardiovascular pharmacology.
[169] K. Morris,et al. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. , 1996, The Journal of clinical investigation.
[170] S. Oparil,et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. , 1995, Journal of applied physiology.
[171] N. Voelkel,et al. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. , 1995, The European respiratory journal.
[172] J. Russell,et al. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. , 1995, American journal of respiratory and critical care medicine.
[173] M. Pasque,et al. Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients. , 1995, Circulation.
[174] S. Das,et al. Nitric oxide: its identity and role in blood pressure control. , 1995, Life sciences.
[175] D. Stewart,et al. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. , 1995, Circulation.
[176] R. Cohen,et al. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. , 1995, Progress in cardiovascular diseases.
[177] J. Loscalzo,et al. Nitric oxide and its role in the cardiovascular system. , 1995, Progress in cardiovascular diseases.
[178] P. Vanhoutte,et al. Endothelium-dependent responses in hypertension. , 1995, Hypertension research : official journal of the Japanese Society of Hypertension.
[179] D. Harrison,et al. Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability. , 1995, The Journal of clinical investigation.
[180] T. Spray,et al. Lung transplantation in children and young adults with cardiovascular disease. , 1995, The Annals of thoracic surgery.
[181] A. Quyyumi,et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. , 1995, Circulation.
[182] G. Pieper,et al. Amelioration by L‐Arginine of a Dysfunctional Arginine/Nitric Oxide Pathway in Diabetic Endothelium , 1995, Journal of cardiovascular pharmacology.
[183] D. Mitchell,et al. AIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals. , 1995, Thorax.
[184] J. Sandoval,et al. Primary pulmonary hypertension in children: clinical characterization and survival. , 1995, Journal of the American College of Cardiology.
[185] A. Denjean,et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. , 1995, American journal of respiratory and critical care medicine.
[186] P. Bruni,et al. Identification of a specific transport system for L-arginine in human platelets. , 1995, Biochemical and biophysical research communications.
[187] P. Dartevelle,et al. Surgical management of unresolved pulmonary embolism. A personal series of 72 patients. , 1995, Chest.
[188] C. Bose,et al. Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. , 1995, Biology of the neonate.
[189] T. Rector,et al. Lack of contribution of nitric oxide to basal vasomotor tone in heart failure. , 1994, The American journal of cardiology.
[190] B. Griffith,et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. , 1994, The Journal of thoracic and cardiovascular surgery.
[191] B. Griffith,et al. Impact of pulmonary hypertension on outcome after single-lung transplantation. , 1994, The Annals of thoracic surgery.
[192] K. Yamane. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. , 1994, Internal medicine.
[193] R. Barst,et al. Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.
[194] R. Cramb,et al. Pulmonary hypertension and pregnancy: a series of eight cases , 1994, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[195] S. Hohnloser,et al. Elevated High-Density Lipoprotein Levels Ameliorate Abnormal Vasoconstriction in Early Atherosclerosis , 2005 .
[196] G. Simonneau,et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. , 1994, Circulation.
[197] J. Stamler,et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. , 1994, Circulation.
[198] K. Ivanova,et al. Soluble Guanylyl Cyclase and Platelet Function a , 1994, Annals of the New York Academy of Sciences.
[199] W. Clarke,et al. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. , 1994, Pulmonary pharmacology.
[200] D. Hayoz,et al. Endothelial dysfunction in chronic heart failure. Experimental and clinical studies. , 1994, Arzneimittel-Forschung.
[201] L. Raij,et al. Glomerular thrombosis in pregnancy: role of the L-arginine-nitric oxide pathway. , 1994, Kidney international.
[202] W. Hurford,et al. Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator. , 1994, Chest.
[203] B. Groves,et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.
[204] G. Patterson,et al. Results of single and bilateral lung transplantation in 131 consecutive recipients. Washington University Lung Transplant Group. , 1994, The Journal of thoracic and cardiovascular surgery.
[205] K. Żmudka,et al. Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. , 1994, Wiener klinische Wochenschrift.
[206] J. Kellum,et al. Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging. , 1994, Life sciences.
[207] R. Trifiletti,et al. Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. , 1994, Biology of the neonate.
[208] W. Vogel,et al. Effects of repeated stress on plasma arginine levels in young and old rats , 1993, Physiology & Behavior.
[209] D. Hayoz,et al. Endothelial function in congestive heart failure. , 1993, American heart journal.
[210] P. Macchiarini,et al. Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension. , 1993, The Journal of thoracic and cardiovascular surgery.
[211] T. Evans,et al. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. , 1993, British journal of clinical pharmacology.
[212] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[213] J. Coligan,et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. , 1993, Journal of immunology.
[214] T. Young,et al. The occurrence of sleep-disordered breathing among middle-aged adults. , 1993, The New England journal of medicine.
[215] T. McMahon,et al. Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. , 1993, Journal of applied physiology.
[216] T Takishima,et al. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. , 1993, Japanese circulation journal.
[217] B. Groves,et al. CORRELATION OF ACUTE PROSTACYCLIN RESPONSE IN PRIMARY (UNEXPLAINED) PULMONARY HYPERTENSION WITH EFFICACY OF TREATMENT WITH CALCIUM CHANNEL BLOCKERS AND SURVIVAL , 1993 .
[218] T. Gasior,et al. Pulmonary hypertension and liver transplantation. , 1993, Anesthesiology.
[219] S. Moncada,et al. The biological and pharmacological role of nitric oxide in platelet function. , 1993, Advances in experimental medicine and biology.
[220] T. Lüscher,et al. Endothelium-Derived Nitric Oxide, Endothelin, and Platelet Vessel Wall Interaction: Alterations in Hypercholesterolemia and Atherosclerosis , 1993, Seminars in thrombosis and hemostasis.
[221] T. Lüscher,et al. Endothelial dysfunction in coronary artery disease. , 1993, Annual review of medicine.
[222] S. Soifer,et al. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. , 1993, The American journal of physiology.
[223] J. Cooke,et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.
[224] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.
[225] S. Rich,et al. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.
[226] H. Palevsky,et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. , 1992, The American review of respiratory disease.
[227] S. Rich,et al. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. , 1992, Journal of the American College of Cardiology.
[228] J. Stamler,et al. Endothelium‐Derived Relaxing Factor Modulates the Atherothrombogenic Effects of Homocysteine , 1992, Journal of cardiovascular pharmacology.
[229] E. Bassenge. Clinical relevance of endothelium-derived relaxing factor (EDRF). , 1992, British journal of clinical pharmacology.
[230] E. Shaffer,et al. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. , 1992, Lancet.
[231] T. Lüscher,et al. Endothelium‐Dependent Regulation of Resistance Arteries: Alterations with Aging and Hypertension , 1992, Journal of cardiovascular pharmacology.
[232] H. Drexler,et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine , 1991, The Lancet.
[233] T. Higenbottam,et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension , 1991, The Lancet.
[234] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[235] S. Moncada,et al. Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.
[236] M. Kramer,et al. Clinical significance of hyperbilirubinemia in patients with pulmonary hypertension undergoing heart-lung transplantation. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[237] J. Cooke,et al. Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta , 1991, Circulation.
[238] E. Sybertz,et al. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. , 1991, Advances in experimental medicine and biology.
[239] J. Krieger,et al. Frequency and mechanism of daytime pulmonary hypertension in patients with obstructive sleep apnoea syndrome. , 1991, Cor et Vasa.
[240] J. Cooke,et al. L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. , 1990, Circulation research.
[241] S. Abman,et al. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. , 1990, The American journal of physiology.
[242] J. Beavo,et al. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. , 1990, Trends in pharmacological sciences.
[243] B. Groves,et al. 26. Pulmonary Hypertension Associated with Hepatic Cirrhosis , 1990 .
[244] J. Rachocka,et al. [Primary pulmonary hypertension in children]. , 1990, Wiadomosci lekarskie.
[245] E. Sforza,et al. Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients. , 1989, Chest.
[246] J. Bultinck,et al. Pulmonary fat embolism presenting as chronic respiratory failure. , 1989, The European respiratory journal.
[247] J. Krieger,et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. , 1988, The American review of respiratory disease.
[248] W. Edwards,et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. , 1987, Journal of the American College of Cardiology.
[249] D. Buff. Primary pulmonary hypertension. , 1987, Annals of internal medicine.
[250] S. Moncada,et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.
[251] J. Haze,et al. Obstructive sleep apnea. , 1987, Cranio : the journal of craniomandibular practice.
[252] W. J. Visek,et al. Arginine needs, physiological state and usual diets. A reevaluation. , 1986, The Journal of nutrition.
[253] L. Zieve. Conditional deficiencies of ornithine or arginine. , 1986, Journal of the American College of Nutrition.
[254] G. Guyatt,et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.
[255] V. Fuster,et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.
[256] R. San Antonio,et al. Laennec's cirrhosis and primary pulmonary hypertension. , 1980, American heart journal.
[257] P. Ogburn,et al. Levels of free fatty acids and arachidonic acid in pregnancy and labor. , 1980, The Journal of laboratory and clinical medicine.
[258] Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. , 1980, Annals of internal medicine.
[259] S. Sothy,et al. Carbohydrate and lipid metabolism during human labor: free fatty acids, glucose, insulin, and lactic acid metabolism during normal and oxytocin-induced labor for postmaturity. , 1976, Metabolism: clinical and experimental.
[260] A. Fishman. Dietary Pulmonary Hypertension , 1974, Circulation research.
[261] G. Kerr. The Free Amino Acids of Serum During Development of Macaca mulatto II. During Pregnancy and Fetal Life , 1968, Pediatric Research.
[262] G. H. Nelson,et al. Alterations of plasma free fatty acids and glucose during labor. , 1967, American journal of obstetrics and gynecology.
[263] H. Mendelow,et al. CONCURRENT "ACTIVE JUVENILE CIRRHOSIS" AND "PRIMARY PULMONARY HYPERTENSION". , 1965, The American journal of medicine.
[264] L. Dunn,et al. PRIMARY PULMONARY HYPERTENSION IN PREGNANCY. , 1964, Obstetrical & gynecological survey.
[265] R. Naeye. "Primary" Pulmonary Hypertension with Coexisting Portal Hypertension: A Retrospective Study of Six Cases , 1960, Circulation.
[266] E. Craige,et al. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. , 1951, A.M.A. archives of pathology.